Background: Peripheral leukocytes in patients with atopic dermatitis (AD) have elevated phosphodiesterase-4 activity, which is associated with production of proinflammatory mediators. OPA-15406 is a phosphodiesterase-4 inhibitor with high selectivity for phosphodiesterase-4-B.
This study was conducted in compliance with International Conference on Harmonization good clinical practice guidelines for conducting, recording, and reporting clinical trials, and for archiving essential documents. 1 Consistent with ethical principles for the protection of human research subjects, 2 no trial procedures were performed on trial candidates until written consent had been obtained. The informed consent form, protocol, and amendments for the study were submitted to and approved by the institutional review board or independent ethics committee for each respective trial site or country.
Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by pruritic erythematous skin lesions and associated cutaneous dysfunction (eg, barrier-disrupted skin). 3 The onset of AD occurs most commonly between 3 and 6 months of age, with approximately 60% of patients developing the condition in the first year of life and 90% by 5 years of age. [4] [5] [6] The majority of affected individuals have resolution of disease during childhood, although 10% to 30% of patients maintain the condition throughout their lives, and a small number of others develop first symptoms as adults. 4, 7 It has been estimated that approximately 18 million people are living with AD in the United States, many with undiagnosed disease. 8 AD cannot be cured, but prompt and effective management can greatly improve both the symptoms and quality of life of affected individuals. According to guidelines from the American Academy of Dermatology, 4 when emollient use and good skin care are insufficient to control AD, pharmacologic treatment should start with mild-to moderatepotency topical corticosteroids. If this approach is unsuccessful, treatment with calcineurin inhibitors can be considered. For severe AD that remains refractory to topical agents, treatment may be intensified to ultraviolet phototherapy and systemic immunomodulators. Although current pharmacotherapeutic approaches have proven to be efficacious in clinical trials, 4,9-13 each has limitations. Extended use of topical corticosteroids is associated with cutaneous atrophy 3 and can sometimes have systemic side effects, such as suppression of the hypothalamic-pituitaryadrenal axis, especially in children.
14 Available topical calcineurin inhibitors carry boxed warnings posing some limitations on their long-term use, based on possible associations with lymphomas and skin malignancies in animal studies. 15, 16 However, clinical studies in human beings have failed to identify an association between topical calcineurin inhibitor use and malignancies, 17 with the possible exception of a very slightly increased risk of skin lymphomas in patients with severe AD. 18 Peripheral blood leukocytes in patients with AD have increased phosphodiesterase-4 (PDE4) activity, [19] [20] [21] which has been associated with higher production of the proinflammatory mediators tumor necrosis factor-alfa, interleukin (IL)-17, IL-22, and interferon-g and lower production of the antiinflammatory mediator IL-10. 21 In pharmacologic analyses, the new chemical entity OPA-15406 exhibited highly selective inhibitory activity against PDE4 subtypes, particularly subtype B (IC 50 = 11.2 nmol/L), and improved skin condition in relevant animal models of AD (unpublished data). This report evaluates the clinical activity, pharmacokinetics, and tolerability of 2 concentrations of OPA-15406 ointment in adult and adolescent patients with mild or moderate AD.
METHODS

Study design
This was a phase-II, randomized, 24 affected by AD at baseline could not be more than 40%, but had to be at least 5%. The face, neck, and head were not treated under the protocol. Patients were required to have had a previous positive but inadequate response to 1 or more standard therapies for AD or were currently unable to use a previously successful treatment. Exclusion criteria included having received systemic therapy or phototherapy within 28 days, or use of topical corticosteroids or calcineurin inhibitors within 7 days of study entry.
Eligible patients were randomized into 3 treatment groups to receive OPA-15406 0.3% (wt/wt), OPA-15406 1% (wt/wt), or vehicle on a double-blind basis. During the 8-week treatment period, patients were instructed to apply a thin film of study ointment to affected areas twice daily, with applications occurring approximately 12 hours apart. The amount applied was approximately 1 g of ointment per every 4% BSA to be treated. Assessments were conducted pretherapy (baseline) and at weeks 1, 2, 4, 6, and 8.
Thirty dermatology-specialty research centers participated in the study from the United States (ClinicalTrials.gov identifier: NCT02068352), Poland (European Clinical Trials Database number: 2013-003899-12), and Australia.
Assessments
Patients were assessed at each visit by a board-certified dermatologist or country-specific equivalent using the 6-point IGA (0 = no disease to 5 = very severe disease) 4 and the Eczema Area and Severity Index (EASI). 25 Patient-reported effects were based on a 100-mm visual analog scale (VAS) for pruritus, 26 the adult Dermatology Life Quality Index (DLQI) 27 for patients 17 years of age or older, and the Children's DLQI 28 for patients 16 years of age or younger.
Pharmacokinetics
Nine patients from 6 centers also consented to provide blood samples at baseline and week 4 for pharmacokinetic evaluation of OPA-15406 (5 in the 0.3% group and 4 in the 1% group). Blood samples were collected before and 2, 4, and 8 hours after the first of the twice-daily doses. Plasma samples were analyzed by high-performance liquid chromatography with tandem mass spectrometric detection. Pharmacokinetic parameters were determined using noncompartmental analysis performed with Phoenix WinNonlin, Version 6.3 (Pharsight Corporation, Princeton, NJ).
Statistical analysis
Forty patients per treatment group provided more than 80% power for each comparison of OPA-15406 versus vehicle at a 2-sided significance level 0.05, assuming response rates of 0.53 and 0.20, respectively. The primary end point was incidence of success at week 4 in IGA score, defined as a final score of 0 or 1 with at least a 2-grade reduction from baseline. To control the overall type I error rate of 0.05, a 2-step testing procedure was applied: OPA-15406 1% versus vehicle first, and OPA-15406 0.3% versus vehicle next only if the first test was statistically significant (P \.05).
For the primary analysis, patients without an IGA score at a scheduled visit were treated as nonresponders for that visit. Comparisons of incidences of success between each OPA-15406 level and vehicle were conducted by Cochran-MantelHaenszel test, stratified by geographic region and age group. The 95% Wald confidence intervals were calculated for the differences of incidence between each OPA-15406 concentration level and vehicle. Subgroup analyses for the primary efficacy variable were provided by age group (\18 or $18 years), geographic region, IGA (mild, moderate), and percent BSA treated (5%-25%, [25%) at baseline.
Change (or percentage change) from baseline in overall IGA score, EASI score, VAS score, and DLQI were analyzed using analysis of covariance with treatment, region, and age group as fixed terms and baseline score as covariate, based on last observation carried forward data.
RESULTS
Patients
A total of 121 patients were randomly assigned to receive OPA-15406 0.3% (n = 41), OPA-15406 1% (n = 43), or vehicle (n = 37) (Fig 1) . All patients visual analog scale J AM ACAD DERMATOL VOLUME jj, NUMBER j received at least 1 dose of study ointment and were analyzed for efficacy and safety. Overall, 27 (22%) patients discontinued prematurely, 10 (24%) in the OPA-15406 0.3% group, 8 (19%) in the OPA-15406 1% group, and 9 (24%) in the vehicle group. Three of the early discontinuations were attributed to adverse events potentially related to study treatment, including 1 case of worsening erythema/pruritus (OPA-15406 0.3%), 1 case of AD exacerbation (vehicle), and 1 case of application site irritation (vehicle). One protocolspecified withdrawal occurred because of pregnancy in a patient who received 30 days of OPA-15406 1%; the patient subsequently delivered a full-term healthy baby. In all, 37 (31%) patients enrolled with an IGA score of 2 and 84 (69%) patients enrolled with an IGA score of 3. At baseline, the overall study population had a mean EASI score of 9.5 6 5.2, a mean VAS pruritus score of 61.7 6 24.0 mm, and a mean affected BSA percentage of 13% 6 8.6%. Of enrolled patients, 20% were younger than 18 years of age. Baseline characteristics were adequately balanced among treatment groups (Table I) .
Effectiveness
The prespecified primary end point was the rate of successful responses on the IGA at week 4. A successful response was defined as a score of 0 (clear) or 1 (almost clear), with at least a 2-grade reduction from the baseline score of 2 (mild) or 3 (moderate). At week 4, success rates were 2.7% for vehicle, 14.6% for OPA-15406 0.3% (P = .0690 vs vehicle), and 20.9% for OPA-15406 1% (P = .0165 vs vehicle) (Fig 2, A) . No appreciable subgroup differences were observed in success rate when analyzed by age, percentage of affected BSA at baseline, or geographic region (Fig 3) , although patients with a baseline IGA score of 3 demonstrated a numerically better IGA response rate than those with a baseline IGA score of 2.
Mean rates at which patients reached an IGA score of 0 or 1, with or without a 2-grade reduction from baseline score, were 10.0% for vehicle, 24.4% for OPA-15406 0.3% (P = .1287 vs vehicle), and 30.2% for OPA-15406 1% (P = .0354 vs vehicle) at week 4 (Fig 2, B) . Whether based on IGA success rate (Fig 2, A) or an IGA score of 0 or 1 (Fig 2, B) , disease severity improved relatively rapidly (week 2-4) in the OPA-15406 1% group, and early positive responses were sustained until the end of treatment (week 8) (Fig 2) .
EASI mean scores decreased (indicating disease improvement) at week 1 in the OPA-15406 1% treatment group (À2.37; P = .0098 vs vehicle), and this trend was maintained at all subsequent study time points (Fig 4, A) . This translated into a 31.4% improvement at week 1 (P = .0005 vs vehicle [6.0%]), a 39.0% change by week 2 (P = .0001 vs vehicle [3.0%]), and a sustained response through week 8 (Fig 4, B) . EASI percentage changes from baseline were also numerically improved at all time points in the OPA-15406 0.3% group (P = .0303 OPA-15406 0.3% vs vehicle at week 2), although the treatment effects were smaller than those observed with OPA-15406 1%.
In patient-reported assessments, the OPA-15406 1% group exhibited a rapid and sustained improvement in AD-associated pruritus relative to the vehicle J AM ACAD DERMATOL VOLUME jj, NUMBER j group (Fig 5, A) . The mean VAS pruritus scores improved from moderate (63.7 6 20.3 mm) to mild (40.5 6 27.1 mm) within 1 week, representing a 36.4% change from baseline. Improvements in pruritus were less dramatic in the OPA-15406 0.3% group. Change from baseline in response to question 1 of the DLQI/Children's DLQI, ie, ''How itchy, scratchy and painful has your skin been over the last week?'' also demonstrated statistically significant improvement (P = .0082) in patients treated with OPA-15406 1% by week 1. Overall, therapy with OPA-15406 1% resulted in early improvements in total quality-of-life scores by week 1 (P = .0037 vs vehicle) (Fig 5, B) , representing a 37.2% change from baseline.
Pharmacokinetic analyses
Among the 9 patients with pharmacokinetics the percentage of overall BSA treated ranged from 5% to 33%; 1 of the 9 had more than 25% of BSA treated. After topical application, plasma levels of OPA-15406 were low for both the 0.3% and the 1% formulations on the first day of dosing, as demonstrated by low maximum plasma concentration after administration (3.18 and 4.74 ng/mL, respectively) and area under the curve values (16.0 and 20.7 ng * h/mL, respectively) (Table II) . Pharmacokinetic parameters at week 4 were similar to those on day 1, indicating no apparent accumulation of active drug after multiple twice-daily administrations of OPA-15406.
Tolerability
Of the 121 patients enrolled in this study, 62 (51%) experienced adverse events (18 In all, 26 patients exhibited worsening of their AD, making this the most frequent adverse event in each treatment group (Table III) . The worsening occurred The remaining treatment-related adverse events were yeast infection in 1 patient in the OPA-15406 1% group (study verbatim: vulvovaginal mycotic infection) and 1 case each of application site pain, erythema, and pruritus in the OPA-15406 0.3% group and application site irritation and pruritus in the vehicle group. All treatment-related adverse events were mild to moderate in intensity.
Five adverse events were classified as serious; none were related to study medication. In the OPA-15406 0.3% group, there was 1 newly diagnosed case of multiple sclerosis in a patient with family history of multiple sclerosis, and 1 case of abnormal liver function test results (meeting Hy law criteria) in a patient after acetaminophen/codeine combination therapy for tooth extraction pain. In the OPA-15406 1% group, 1 case each of worsening of depression, giardiasis infection, and splenic rupture caused by a motor accident was reported.
DISCUSSION
In this study, the PDE4 inhibitor OPA-15406, applied topically as a 0.3% (wt/wt) or 1% (wt/wt) ointment, provided therapeutic benefit to patients with mild to moderate AD. The benefit was documented by clinician-reported outcomes, including success rate (based on IGA score) and percentage change on the EASI score. OPA-15406 treatment was also associated with improvements in patient-reported outcomes, notably improvements in VAS pruritus scores, with significant treatment effects observed for the 1% formulation relative to vehicle at most time points in the study. Pruritus, a hallmark of AD, can lead to skin damage by J AM ACAD DERMATOL VOLUME jj, NUMBER j excoriation and the development of secondary infection, which further aggravates the disease. 29 Nocturnal scratching is one of the most common symptoms of AD and often results in sleep disturbances and dramatic impairment in quality of life, especially in children. Thus, a new treatment modality with a direct positive impact on limiting pruritus, while simultaneously decreasing inflammation in affected skin, has the potential to substantially improve therapeutic options for the management of AD.
Several other features of OPA-15406 therapy were noted in this study. First, the anti-inflammatory and antipruritic effects had rapid onset, with statistically significant differences from vehicle in some parameters within 1 week of treatment. In general, the positive effects of OPA-15406 were sustained through the week-8 visit, but the differences between active and vehicle arms diminished slightly as skin condition improved in the vehicle group over time, presumably as a result of the emollients in the ointment base. Second, in all assessments, OPA-15406 1% exhibited better clinical and patient-reported outcomes than OPA-15406 0.3%, suggesting a clear dose response. Finally, the nature and number of treatment-related adverse events, combined with the negligible systemic exposure after OPA-15406 application, indicated an overall favorable tolerability profile for this new topical agent.
Our study has limitations because of the compound's early developmental stage, eg, the relatively small number of enrolled patients, and it is difficult to predict how OPA-15406 will compare with topical calcineurin inhibitors, topical corticosteroids, or other PDE4 inhibitors. Moreover, further investigations in pediatric patient populations (age \10 years) will be needed. Nonetheless, the consistent and beneficial effects observed in this study support further evaluation of OPA-15406 1% ointment for the treatment of AD in large randomized phase-III trials. Plasma samples were collected from a subset of patients on days 1 and 29 (week-4 visit) and subjected to pharmacokinetic analysis (see ''Methods'' section). AUC 0e8h , Area under the concentration curve from 0-8 hours; C max , maximum plasma concentration after administration; t max , time to reach C max . 
